(ERAS) Erasca - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 4.559m | Total Return 980.4% in 12m

Stock: Cancer Therapies, Drug Development, Oncology Treatments

Total Rating 45
Risk 69
Buy Signal 0.98
Biotechnology -0.2
Biotechnology +0.4
Market Cap: 4,559m
Avg Trading Vol: 76.3M USD
ATR: 7.00%
Peers RS (IBD): 99.8
Risk 5d forecast
Volatility 80.7%
Relative Tail Risk -8.84%
Reward TTM
Sharpe Ratio 2.82
Alpha 950.74
Character TTM
Beta 1.583
Beta Downside 1.826
Drawdowns 3y
Max DD 67.88%
CAGR/Max DD 1.13

EPS (Earnings per Share)

EPS (Earnings per Share) of ERAS over the last years for every Quarter: "2021-03": -0.745, "2021-06": -1.2, "2021-09": -0.46, "2021-12": -0.26, "2022-03": -0.31, "2022-06": -0.3, "2022-09": -0.29, "2022-12": -1.06, "2023-03": -0.22, "2023-06": -0.21, "2023-09": -0.2, "2023-12": -0.2, "2024-03": -0.23, "2024-06": -0.29, "2024-09": -0.11, "2024-12": -0.11, "2025-03": -0.11, "2025-06": -0.12, "2025-09": -0.11, "2025-12": -0.1,
EPS CAGR: 6.64%
EPS Trend: 55.3%
Last SUE: 0.18
Qual. Beats: 0

Revenue

Revenue of ERAS over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 5.58, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 4.196, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Rev. Trend: 11.3%
Last SUE: 0.00
Qual. Beats: 0

Description: ERAS Erasca March 05, 2026

Erasca, Inc. is a clinical-stage biotechnology company specializing in precision oncology. The company develops therapies targeting RAS/MAPK pathway-driven cancers, a common oncogenic pathway.

Erascas primary drug candidate, naporafenib, is in late-stage clinical trials for NRAS-mutated melanoma. The company also has multiple other drug candidates in various stages of development, including treatments for pan-RAS, pan-KRAS, EGFR, and recurrent glioblastoma. The biotechnology sector is characterized by lengthy and expensive drug development processes.

Erascas business model involves licensing agreements with larger pharmaceutical companies like Novartis, Katmai Pharmaceuticals, and NiKang Therapeutics to develop and commercialize certain drug candidates. This strategy can reduce R&D costs and leverage established commercialization channels. To further understand Erascas market position, consider exploring its pipeline comparisons on ValueRay.

Headlines to watch out for

  • Naporafenib Phase 3 trial results significantly impact future revenue
  • Clinical trial failures for pipeline drugs decrease stock value
  • Regulatory approval delays for oncology therapies increase costs
  • Licensing agreements with Novartis, others provide development funding

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.24 > 0.02 and ΔFCF/TA -2.34 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.24 > 3% & CFO -95.5m > Net Income -124.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.04 > 1.5 & < 3
Outstanding Shares: last quarter (283.5m) vs 12m ago 21.26% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.83%; Δ -0.83% > 0%)
Interest Coverage Ratio: -26.29 > 6 (EBITDA TTM -126.4m / Interest Expense TTM -4.92m)

Altman Z'' -15.00

A: 0.65 (Total Current Assets 286.2m - Total Current Liabilities 28.5m) / Total Assets 396.2m
B: -2.25 (Retained Earnings -892.2m / Total Assets 396.2m)
C: -0.29 (EBIT TTM -129.5m / Avg Total Assets 449.3m)
D: -12.56 (Book Value of Equity -891.6m / Total Liabilities 71.0m)
Altman-Z'' Score: -18.20 = D

Beneish M

DSRI: none (Receivables 2.50m/2.30m, Revenue 0.0/4.20m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.59 (AQ_t 0.17 / AQ_t-1 0.29)
SGI: none (Revenue 0.0 / 4.20m)
TATA: -0.07 (NI -124.5m - CFO -95.5m) / TA 396.2m)
Beneish M-Score: cannot calculate (missing components)

What is the price of ERAS shares?

As of March 26, 2026, the stock is trading at USD 15.99 with a total of 5,583,350 shares traded.
Over the past week, the price has changed by +18.44%, over one month by +18.80%, over three months by +359.48% and over the past year by +980.41%.

Is ERAS a buy, sell or hold?

Erasca has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ERAS.
  • StrongBuy: 5
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ERAS price?

Issuer Target Up/Down from current
Wallstreet Target Price 16.8 5.1%
Analysts Target Price 16.8 5.1%

ERAS Fundamental Data Overview March 26, 2026

P/B = 13.9547
Revenue TTM = 0.0 USD
EBIT TTM = -129.5m USD
EBITDA TTM = -126.4m USD
Long Term Debt = 47.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.07m USD (from shortTermDebt, last quarter)
Debt = 47.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.33b USD (4.56b + Debt 47.1m - CCE 276.1m)
Interest Coverage Ratio = -26.29 (Ebit TTM -129.5m / Interest Expense TTM -4.92m)
EV/FCF = -45.31x (Enterprise Value 4.33b / FCF TTM -95.6m)
FCF Yield = -2.21% (FCF TTM -95.6m / Enterprise Value 4.33b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.35m) / Revenue TTM)
Tobins Q-Ratio = 10.93 (Enterprise Value 4.33b / Total Assets 396.2m)
Interest Expense / Debt = 8.12% (Interest Expense 3.83m / Debt 47.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -102.3m (EBIT -129.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.04 (Total Current Assets 286.2m / Total Current Liabilities 28.5m)
Debt / Equity = 0.14 (Debt 47.1m / totalStockholderEquity, last quarter 325.2m)
Debt / EBITDA = 0.21 (negative EBITDA) (Net Debt -26.7m / EBITDA -126.4m)
Debt / FCF = 0.28 (negative FCF - burning cash) (Net Debt -26.7m / FCF TTM -95.6m)
Total Stockholder Equity = 361.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.72% (Net Income -124.5m / Total Assets 396.2m)
RoE = -34.48% (Net Income TTM -124.5m / Total Stockholder Equity 361.2m)
RoCE = -31.71% (EBIT -129.5m / Capital Employed (Equity 361.2m + L.T.Debt 47.1m))
RoIC = -28.32% (negative operating profit) (NOPAT -102.3m / Invested Capital 361.2m)
WACC = 11.50% (E(4.56b)/V(4.61b) * Re(11.55%) + D(47.1m)/V(4.61b) * Rd(8.12%) * (1-Tc(0.21)))
Discount Rate = 11.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 53.34%
[DCF] Fair Price = unknown (Cash Flow -95.6m)
EPS Correlation: 55.33 | EPS CAGR: 6.64% | SUE: 0.18 | # QB: 0
Revenue Correlation: 11.27 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.11 | Chg7d=+0.004 | Chg30d=+0.008 | Revisions Net=+2 | Analysts=7
EPS current Year (2026-12-31): EPS=-0.57 | Chg7d=-0.091 | Chg30d=-0.106 | Revisions Net=+1 | Growth EPS=-29.0% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-0.54 | Chg7d=+0.015 | Chg30d=-0.011 | Revisions Net=+0 | Growth EPS=+4.6% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)

Additional Sources for ERAS Stock

Fund Manager Positions: Dataroma | Stockcircle